PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease

Kannenkeril D, Bosch A, Kolwelter J, Striepe K, Pietschner R, Ott C, Schiffer M, Achenbach S, Schmieder R (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

European Heart Journal Oxford University Press

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: 2674-2674

Conference Proceedings Title: EUROPEAN HEART JOURNAL

DOI: 10.1093/eurheartj/ehac544.2674

Authors with CRIS profile

Agnes Bosch Department of Medicine 4 – Nephrology and Hypertension Julie Kolwelter Department of Medicine 2 – Cardiology and Angiology Kristina Striepe Professur für Innere Medizin (Nephrologie) Robert Pietschner Department of Medicine 4 – Nephrology and Hypertension Christian Ott Department of Medicine 4 – Nephrology and Hypertension Mario Schiffer Lehrstuhl für Innere Medizin IV Susanne Achenbach Department of Transfusion Medicine and Haemostaseology Roland Schmieder Professur für Innere Medizin (Nephrologie)

How to cite

APA:

Kannenkeril, D., Bosch, A., Kolwelter, J., Striepe, K., Pietschner, R., Ott, C.,... Schmieder, R. (2022). PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease. In EUROPEAN HEART JOURNAL (pp. 2674-2674). OXFORD: OXFORD UNIV PRESS.

MLA:

Kannenkeril, Dennis, et al. "PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease." Proceedings of the EUROPEAN HEART JOURNAL OXFORD: OXFORD UNIV PRESS, 2022. 2674-2674.

BibTeX: Download